I think it's a really important question, and I think we've made great progress in recent years with the research agenda, with funding on both the infrastructure and equipment side and on the human resources side: the CRC side, the Vanier scholarships, and so forth. And with the direct funds and the commitment to an indirect cost program, the pieces of the package are there. I think we'll have to be mindful of what international comparators say in these areas, and it is true by international comparators, as recent studies commissioned by AUCC and the G13 have shown, that we are still underfunding, in relative, comparative terms, the full cost of research.
That said, I am quite comfortable with even more emphasis on outcomes measures, especially in those programs that are aimed at the applied and innovation and commercialization end of the research spectrum.
The question of time horizons is extremely important. We must continue to fund basic research, because it is the wellspring of applied research and commercializable technologies and processes. We can apply outcomes measures more directly to the commercializable end of the process than we can to the basic end of the process, where peer review remains the classic comparator of quality internationally. But the outcomes measures and the vehicles for delivering on commercialization—through innovation and research parks, through tech transfer offices, through the co-location of venture capital companies with innovation and research parks, as we have done at McMaster—I think are the way forward.